Хуудас 1 -аас 20 үр дүн
RELATED APPLICATION
This application is a national stage filing under 35 U.S.C. .sctn. 371 of International Application No. PCT/GB2015/051893, filed Jun. 29, 2015, which was published under PCT Article 21(2) in English, the entire disclosure of which is incorporated by reference herein in its
BACKGROUND
1. Field
The disclosure of the present patent application relates to andrographolide derivatives, and particularly to isoandrographolide-19-propionate for treatment of non-alcoholic fatty liver disease (NALFD), the use of the compound in hepatoprotective applications, and methods of
DESCRIPTION
Background of the Invention
Field of the Invention
The invention generally relates to lipid-lowering therapies. In particular, the invention provides a nuclear cholesterol metabolite, 5-cholesten-3.beta., 25-diol 3-sulphate, that decreases lipid biosynthesis and increases cholesterol
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention generally relates to lipid-lowering therapies. In particular, the invention provides a nuclear cholesterol metabolite, 5-cholesten-3.beta., 25-diol 3-sulphate, that decreases lipid biosynthesis and increases cholesterol secretion
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention generally relates to lipid-lowering therapies. In particular, the invention provides a nuclear cholesterol metabolite, 5-cholesten-3.beta., 25-diol 3-sulphate, that decreases lipid biosynthesis and increases cholesterol secretion
CROSS REFERENCE TO RELATED APPLICATIONS AND CLAIM OF PRIORITY
This application claims benefit under 35 U.S.C. 119(e), 120, 121, or 365(c), and is a National Stage entry from International Application No. PCT/KR2015/010745, filed Oct. 13, 2015, which claims priority to the benefit of Korean Patent
The present application is a U.S. National Application filed under 35 USC 371 of PCT/FR97/00196, filed Jan. 31, 1997 based upon French application Serial No. 96/01276 filed Feb. 2, 1996.
The present invention relates to dermocosmetic compositions containing retinal and to a process for improving
SUMMARY OF THE INVENTION
The present invention relates to obeticholic acid, an agonist for FXR, processes of preparation for obeticholic acid, pharmaceutical formulations comprising obeticholic acid, and the therapeutic use of the same.
##STR00002##
The present invention relates to a crystalline
SUMMARY OF THE INVENTION
The present invention relates to obeticholic acid, an agonist for FXR, processes of preparation for obeticholic acid, pharmaceutical formulations comprising obeticholic acid, and the therapeutic use of the same.
##STR00002##
The present invention relates to a crystalline
SUMMARY OF THE INVENTION
The present invention relates to obeticholic acid, an agonist for FXR, processes of preparation for obeticholic acid, pharmaceutical formulations comprising obeticholic acid, and the therapeutic use of the same.
##STR00002##
The present invention relates to a crystalline
SUMMARY OF THE INVENTION
The present invention relates to obeticholic acid, an agonist for FXR, processes of preparation for obeticholic acid, pharmaceutical formulations comprising obeticholic acid, and the therapeutic use of the same
##STR00002##
The present invention relates to a crystalline
SUMMARY OF THE INVENTION
The present invention relates to obeticholic acid, an agonist for FXR, processes of preparation for obeticholic acid, pharmaceutical formulations comprising obeticholic acid, and the therapeutic use of the same.
##STR00002##
The present invention relates to a crystalline
SUMMARY OF THE INVENTION
The present invention relates to obeticholic acid, an agonist for FXR, processes of preparation for obeticholic acid, pharmaceutical formulations comprising obeticholic acid, and the therapeutic use of the same.
##STR00002##
The present invention relates to a process for the
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not applicable.
BACKGROUND OF THE INVENTION
The majority of cancer-related deaths occur after primary therapy has been completed, mostly due to recurrence of the cancer or development of second cancers. Major efforts are underway to
TECHNICAL FIELD
The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, which comprises an oxyntomodulin derivative as an active ingredient, and to a method for treating hyperlipidemia, fatty liver disease or arteriosclerosis